HydroxyColl™is a novel bone graft substitute which combines bone’s two main constituents, collagen and hydroxyapatite, in a bioactive scaffold for the repair of bone tissue defects. Collagen is a natural biopolymer while hydroxyapatite is the ceramic mineral found in naturally occurring bone tissue.
The HydroxyColl™scaffold is a highly porous (>99%) bioactive and biodegradable matrix that is specifically optimised to facilitate and promote bone tissue healing. It performs as an osteoinductive scaffold without the need for expensive and potentially dangerous bone regenerative agents (such as Bone Morphogenetic Proteins). HydroxyColl™’s mechanical properties, in combination with the excellent biocompatibility, biodegradability and pore architecture of a collagen-only scaffold, offer superior regenerative performance to currently available bone graft substitutes.
HydroxyColl™is capable of directing bone regeneration while supporting the body’s own natural healing process and is completely replaced by newly formed, healthy bone tissue. In vitro and pre-clinical performance has demonstrated superior results to existing competitor products and to the current “gold standard” autograft procedure.
|Biodegradable||Resorbed into the body over time|
|Biocompatible and Bioactive||Facilitates complete osteogenesis|
|High porosity||Facilitates bone cell migration through matrix
Increased cellular nutrient and waste exchange
|High permeability||Facilitates conductivity of fluid through the matrix|
|Mechanically strong||Facilitates handling and ease of use
Provides structure within which bone reforms
|High degree of pore interconnectivity||Prevents avascular necrosis
Increases cell mobility
HydroxyColl™ – How it works
Despite the numbers of bone graft substitutes currently on the market as autograft replacements, none have successfully replaced the clinical “gold standard”, autografting, as a result of disappointing performance. Many of these traditional approaches are based on poor science and a lack of understanding of the body’s natural healing process.
HydroxyColl™ is not a traditional technology, it was developed out of a single innovative idea, nearly 10 years ago, to use bioactive materials to support the body’s own natural healing process. HydroxyColl™ uses materials found within the body to promote the restoration of the human body.
HydroxyColl™ is an innovative bone graft substitute and is the culmination of over a decade of world class collagen-based tissue regeneration research. HydroxyColl™ is a highly absorbent material that exhibits a number of characteristics that when combined, result in a superior bone graft substitute material. By providing an environment that is attractive and supportive to the bone regenerative cells that are abundant at a bone defect or fracture site, HydroxyColl™ promotes the rapid production of bone extracellular matrix, followed by a cascade of mineralisation throughout the healing defect. Since HydroxyColl™ is made of the body’s own natural building blocks, it seamlessly supports and promotes regeneration while simultaneously not acting as a barrier or impediment to the bone regenerative and formative processes within the defect site.
HydroxyColl™ is an “off the shelf device that is easily cut and shaped to fit any bone defect and is designed to support the body’s own natural healing process, encouraging infiltration of regenerative host cells. HydroxyColl™’s high porosity, permeability, and uniquely controllable pore size, ensure even distribution of regenerative cells, resulting in homogenous new bone matrix formed throughout the entire defect, producing superior levels of healing,
The naturally-osteoinductive hydroxyapatite phase encourages rapid mineralisation of new bone matrix, resulting in natural and healthy bone within the defect. The result is complete and seamless healing with new and healthy, fully functioning bone, naturally.
eCM is the official research Journal of AOTrauma, Swiss Society for Biomaterials (SSB)and the Tissue & Cell Engineering Society (TCES). eCM provides a forum for publication of preclinical research in the musculoskeletal field (Trauma, Maxillofacial (including dental), Spine and Orthopaedics) and the cells and materials used in the replacement, repair or regeneration of these tissues. eCM is “The leading Journal” in the fields of musculoskeletal research and biomaterials. 2010 Impact Factor (IF) for eCM is 9.650.